Actinium Pharmaceuticals, Inc, also called Actinium Pharmaceuticals, is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Read More Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.